{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:10Z","timestamp":1792131010161,"version":"4.4.0"},"reference-count":44,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T00:00:00Z","timestamp":1529625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008397","name":"Velux Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Steroid treatment can accelerate visual recovery in patients with optic neuritis (ON), but it is unknown whether the timing of the start of treatment influences the outcome. The main purpose of this observational study was to assess the effect of early onset steroid treatment of ON on visual prognosis and retinal morphology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty\u2010nine patients with acute mild\/moderate (<jats:italic>n<\/jats:italic>\u00a0=\u00a021) or severe (<jats:italic>n<\/jats:italic>\u00a0=\u00a028) ON, and an equal number of healthy controls were enrolled. Patients with severe ON either received early onset steroid treatment (initiated within 1\u00a0week of presentation with visual loss) (<jats:italic>n<\/jats:italic>\u00a0=\u00a09), late\u2010onset treatment (initiated after 1\u00a0week) (<jats:italic>n<\/jats:italic>\u00a0=\u00a013), or no treatment (<jats:italic>n<\/jats:italic>\u00a0=\u00a06). Visual function and retinal morphology was studied after 6 and 12\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All measures of visual function had improved after 6\u00a0months (<jats:italic>p\u00a0<\/jats:italic>\u2264<jats:italic>\u00a0<\/jats:italic>0.03) in the three groups with severe ON. This was not the case for Rayleigh match setting range (SR) in the nontreated group (<jats:italic>p\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.24), or for SR (<jats:italic>p\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.08) and latency to P100 of visual evoked potential (<jats:italic>p\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.08) in the late\u2010onset treated group. After 12\u00a0months, further improvement occurred in the nontreated and late\u2010treated groups, but not in the early treated group. Macular retinal nerve fiber layer (mRNFL) and ganglion cell plus inner plexiform layer had decreased significantly (<jats:italic>p\u00a0<\/jats:italic>\u2264<jats:italic>\u00a0<\/jats:italic>0.001) in all three groups with severe ON after 6\u00a0months. After 12\u00a0months, only mRNFL had further significantly decreased and only in the late\u2010onset treated group (<jats:italic>p\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The beneficial effects of early onset steroid treatment of ON is limited to a few months whereas the long\u2010term prognosis is independent of the timing of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.1032","type":"journal-article","created":{"date-parts":[[2018,6,22]],"date-time":"2018-06-22T08:47:25Z","timestamp":1529657245000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Time to steroid treatment in severe acute optic neuritis"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8425-5670","authenticated-orcid":false,"given":"Gro Helen","family":"Dale","sequence":"first","affiliation":[{"name":"Department of Neurology Aarhus University Hospital  Aarhus Denmark"},{"name":"Department of Biomedicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Petersen","sequence":"additional","affiliation":[{"name":"Department of Neurology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Bacher Svendsen","sequence":"additional","affiliation":[{"name":"Department of Neurology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Christensen","sequence":"additional","affiliation":[{"name":"Department of Biomedicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Houen","sequence":"additional","affiliation":[{"name":"Department of Autoimmunology and Biomarkers Statens Serum Institut  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toke","family":"Bek","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515590646"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000154521.40686.63"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000094315.19931.90"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8127-y"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090060061023"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260901"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(94)31103-1"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00862-6"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.04.006"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150070172"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516642315"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000131"},{"issue":"5","key":"e_1_2_7_14_1","first-page":"1017","article-title":"The national eye institute visual function questionnaire: Experience of the ONTT. optic neuritis treatment trial","volume":"41","author":"Cole S. R.","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20851"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508091367"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-309704"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002774"},{"issue":"3","key":"e_1_2_7_19_1","first-page":"e010956","article-title":"Treatment of optic neuritis with erythropoietin (TONE): A randomised, double\u2010blind, placebo\u2010controlled trial\u2010study protocol","volume":"6","author":"Diem R.","year":"2016","journal-title":"British Medical Journal Open"},{"issue":"5","key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2013an extension of the modified airlie house classification. ETDRS report number 10. Early treatment diabetic retinopathy study research group","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(87)33349-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.10"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24351"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000135"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq146"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12271"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(02)00428-8"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.230"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000524"},{"issue":"4","key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135245850000600408","article-title":"A meta\u2010analysis of methylprednisolone in recovery from multiple sclerosis exacerbations","volume":"6","author":"Miller D. M.","year":"2000","journal-title":"Multiple Sclerosis"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181aaea32"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-010-1344-7"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137316"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000334"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0720-6"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.009"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/815068"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000421"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514538110"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1479"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517734070"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr264"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034823"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.12.016"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20575"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbrb3.1032","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.1032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T13:22:52Z","timestamp":1694870572000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.1032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,22]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1002\/brb3.1032"],"URL":"https:\/\/doi.org\/10.1002\/brb3.1032","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,22]]},"assertion":[{"value":"2018-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01032"}}